Palisade Bio, Inc. (PALI)
Largest Insider Buys in Sector
PALI Stock Price History Chart
PALI Stock Performance
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Insider Activity of Palisade Bio, Inc.
Over the last 12 months, insiders at Palisade Bio, Inc. have bought $54,718 and sold $192 worth of Palisade Bio, Inc. stock.
On average, over the past 5 years, insiders at Palisade Bio, Inc. have bought $61,448 and sold $192 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Williams Donald Allen (director) — $43,426. Finley John David (CEO, CFO, Director) — $33,005.
The last purchase of 1,000 shares for transaction amount of $4,863 was made by Williams Donald Allen (director) on 2024‑05‑28.
List of Insider Buy and Sell Transactions, Palisade Bio, Inc.
| 2024-05-28 | Williams Donald Allen | director | 1,000 0.1091% | $4.86 | $4,863 | 0.00% | ||
| 2024-05-24 | Finley John David | CEO, CFO, Director | 1,000 0.0994% | $4.81 | $4,810 | -5.91% | ||
| 2024-02-06 | Finley John David | CEO, CFO, Director | 10,000 0.0819% | $0.47 | $4,692 | -14.10% | ||
| 2024-01-31 | Finley John David | CEO, CFO, Director | 10,000 0.0976% | $0.56 | $5,590 | -34.82% | ||
| 2024-01-31 | Williams Donald Allen | director | 10,000 0.1056% | $0.60 | $6,050 | -34.82% | ||
| 2023-09-27 | Finley John David | CEO, CFO, Director | 15,000 0.1655% | $0.54 | $8,088 | -10.10% | ||
| 2023-09-27 | Williams Donald Allen | director | 20,000 0.221% | $0.54 | $10,800 | -10.10% | ||
| 2023-09-14 | Sale | Trenschel Robert J. | director | 300 0.0034% | $0.64 | $192 | -17.60% | |
| 2023-09-13 | Finley John David | CEO, CFO, Director | 15,000 0.2077% | $0.66 | $9,825 | -20.68% | ||
| 2022-09-01 | Finley John David | Chief Financial Officer | 19,481.24 0.0402% | $0.14 | $2,799 | -69.79% | ||
| 2022-08-23 | Finley John David | Chief Financial Officer | 7,350 0.0144% | $0.16 | $1,176 | -73.51% | ||
| 2022-03-29 | Dawson Michael John | Chief Medical Officer | 15,000 0.0958% | $1.14 | $17,093 | -89.84% | ||
| 2022-03-28 | Hallam Thomas | Chief Executive Officer | 10,000 0.0655% | $1.18 | $11,800 | -89.81% | ||
| 2022-03-24 | Finley John David | Chief Financial Officer | 7,500 0.045% | $1.09 | $8,174 | -89.78% | ||
| 2021-09-21 | Finley John David | Chief Financial Officer | 2,000 0.0164% | $2.44 | $4,880 | -62.00% | ||
| 2021-09-21 | Hallam Thomas | Chief Executive Officer | 6,000 0.0502% | $2.49 | $14,940 | -62.00% | ||
| 2021-09-10 | Trenschel Robert J. | director | 2,142 0.0176% | $2.98 | $6,383 | -67.75% | ||
| 2021-09-09 | Trenschel Robert J. | director | 3,400 0.028% | $2.89 | $9,826 | -66.59% | ||
| 2021-09-08 | Trenschel Robert J. | director | 5,000 0.0424% | $2.75 | $13,750 | -63.62% | ||
| 2021-09-07 | Trenschel Robert J. | director | 2,707 0.0215% | $2.78 | $7,525 | -66.09% |
Insider Historical Profitability
| Finley John David | CEO, CFO, Director | 8437 0.9126% | $4.58 | 10 | 0 | <0.0001% |
| Williams Donald Allen | director | 1000 0.3234% | $4.58 | 3 | 0 | |
| Trenschel Robert J. | director | 0 0% | $4.58 | 5 | 1 | |
| JOHE KARL | Chief Scientific Officer | 826304 8.9082% | $4.58 | 0 | 30 | |
| GARR RICHARD | CEO | 240000 2.5874% | $4.58 | 2 | 3 | |
| OLDAKER WILLIAM CLYDE | director | 116939 1.2607% | $4.58 | 7 | 0 | |
| CONRON JOHN | Chief Financial Officer | 51364 0.5537% | $4.58 | 3 | 0 | |
| Daly Richard J | Chief Executive Officer | 23312 0.2513% | $4.58 | 7 | 0 | |
| Hallam Thomas | Chief Executive Officer | 17592 0.1897% | $4.58 | 2 | 0 | <0.0001% |
| Dawson Michael John | Chief Medical Officer | 15000 0.1617% | $4.58 | 1 | 0 | <0.0001% |
| LLOYD JONES JONATHAN BRIAN | Chief Financial Officer | 7859 0.0847% | $4.58 | 2 | 0 |
Institutional Investor Ownership
No records found… | |||||||